On September 2, 2022 Regulus Therapeutics Inc. ( Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), reported that the Company will participate in two upcoming investor conferences (Press release, Regulus, SEP 2, 2022, View Source [SID1234618955]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details are as follows:
Wells Fargo Healthcare Conference taking place September 7-9, 2022, in Boston, MA
H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022, in New York, NY
Jay Hagan, President and Chief Executive Officer of Regulus, will give a live presentation on Monday, September 12, 2022, at 2:30 p.m. ET
A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company’s website at www.regulusrx.com and archived for 30 days following the presentation date.